DiaMedica Therapeutics Inc. announced that it has entered into security purchase agreement with accredited investors to issue a total of 4,720,000 common shares at a purchase price of $2.50 per share for the gross proceeds of $11,800,000 on June 25, 2024. The private placement is expected to close on or about June 28, 2024, subject to the satisfaction of customary closing conditions. The offering and sale of the shares are exempt from registration under Section 4(a)(2) of the United States Securities Act of 1933, as amended and Rule 506 of Regulation D as promulgated thereunder.
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
2.95 USD | 0.00% | +32.88% | +3.87% |
01/07 | DiaMedica Therapeutics Inc. announced that it has received $11.8 million in funding | CI |
27/06 | Transcript : DiaMedica Therapeutics Inc. - Special Call |
EPS Revisions
1st Jan change | Capi. | |
---|---|---|
+3.87% | 11Cr | |
+15.82% | 12TCr | |
+20.35% | 11TCr | |
+17.47% | 2.6TCr | |
-25.31% | 1.94TCr | |
-19.51% | 1.59TCr | |
-19.67% | 1.51TCr | |
-46.87% | 1.51TCr | |
+62.55% | 1.49TCr | |
+6.34% | 1.39TCr |
- Stock Market
- Equities
- DMAC Stock
- News DiaMedica Therapeutics Inc.
- DiaMedica Therapeutics Inc. announced that it expects to receive $11.8 million in funding